OLMA — Olema Pharmaceuticals, Inc. Stock Price, Chart & AI Report

Neutral Jan 9, 2026 • 16:08 UTC The Motley Fool • Jonathan Ponciano

Olema Insider Sells $8 Million in Shares After 300% Stock Surge

Olema Pharmaceuticals board member Ian T. Clark sold approximately $7.9 million worth of shares (264,800 shares) on December 19, representing a complete exit from his direct equity holdings. The sale followed a 326.5% one-year stock surge driven by recent analyst upgrades and encouraging clinical trial updates. The company, focused on breast cancer therapies, has strengthened its balance sheet with a $218.5 million equity raise and maintains $329 million in cash runway into 2028.

OLMA insider sale stock surge biotech clinical trials breast cancer option exercise equity raise

Sentiment note

While the insider sale of $7.9 million could signal profit-taking after a 300%+ surge, the article emphasizes this doesn't necessarily indicate negative company trajectory. The company shows strong operational fundamentals with increased R&D spending, substantial cash reserves ($329M), recent successful equity raise ($218.5M), and encouraging clinical trial results that drove recent analyst upgrades. The insider's complete exit is attributed to liquidity/tax optimization following significant appreciation rather than loss of confidence.

Neutral Nov 18, 2025 • 21:51 UTC GlobeNewswire Inc. • Courtney O'Konek

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Olema Pharmaceuticals plans to launch a public offering of common stock or pre-funded warrants, with TD Cowen acting as book-running manager. The offering is subject to market conditions and regulatory approvals.

OLMA public offering stock biopharmaceutical breast cancer clinical trials

Sentiment note

The company is pursuing a standard public offering to raise capital, which is a typical financial strategy for clinical-stage pharmaceutical companies seeking to fund research and development

Positive Nov 18, 2025 • 17:01 UTC Benzinga • Erica Kollmann

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Martin Shkreli announced shorting Olema Pharmaceuticals stock, criticizing the company's valuation in the SERD drug market. Despite Shkreli's stance, Olema's stock surged over 140% after positive phase 3 results from Roche's breast cancer study, with analysts raising price targets.

OLMA RHHBY Martin Shkreli Olema Pharmaceuticals SERD breast cancer stock shorting

Sentiment note

Stock rose 140% following Roche's positive phase 3 study results, with multiple analysts raising price targets and showing confidence in the company's potential

Positive Oct 18, 2025 • 07:00 UTC GlobeNewswire Inc. • Olema Oncology

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Olema Oncology presented promising Phase 1b/2 trial results showing palazestrant combined with ribociclib demonstrated encouraging progression-free survival and tolerability in ER+/HER2- metastatic breast cancer patients, supporting ongoing Phase 3 clinical trials.

OLMA breast cancer metastatic cancer clinical trial palazestrant ribociclib oncology

Sentiment note

Reported promising clinical trial results with favorable progression-free survival, safety profile, and potential for new treatment paradigm in metastatic breast cancer

Positive May 28, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

Olema Oncology announced the selection of a 90 mg once-daily dose of palazestrant for its Phase 3 OPERA-01 monotherapy trial and OPERA-02 combination trial with ribociclib. The company will present a trial-in-progress poster for OPERA-01 at the ASCO 2025 Annual Meeting.

OLMA Olema Oncology palazestrant OPERA-01 OPERA-02 ribociclib ASCO 2025

Sentiment note

The company has selected the dose for its Phase 3 trials and is advancing its pipeline, which indicates progress and potential for the company.

Positive Apr 30, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight

The metastatic HR+/HER2- breast cancer market is expected to grow due to the launch of several novel emerging therapies, which are anticipated to change the treatment landscape and improve survival outcomes for this patient population.

PFE NVS ARVN OLMA metastatic HR+/HER2- breast cancer targeted therapies personalized medicine

Sentiment note

Olema Pharmaceuticals is developing the metastatic HR+/HER2- breast cancer drug OP-1250.

Positive Apr 25, 2025 • 17:00 UTC GlobeNewswire Inc. • N/A

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Olema Oncology presented preclinical data demonstrating the anti-tumor activity of OP-3136, a KAT6 inhibitor, in prostate, ovarian, and non-small cell lung cancer models. The data showed potent tumor growth inhibition and sustained tumor regression in various cancer models, supporting the potential utility of OP-3136 beyond breast cancer.

OLMA Olema Oncology OP-3136 KAT6 inhibitor preclinical data anti-tumor activity solid tumor models

Sentiment note

The article highlights positive preclinical data for Olema Oncology's drug candidate OP-3136, demonstrating its anti-tumor activity in multiple solid tumor models. This suggests the potential for the drug to be effective in treating various cancer types beyond breast cancer, which is the company's primary focus.

Positive Jan 3, 2025 • 21:30 UTC GlobeNewswire Inc. • N/A

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted stock options to three new employees to purchase a total of 26,200 shares of the company's common stock. The stock options have a 10-year term and an exercise price of $5.57 per share.

OLMA Olema Pharmaceuticals stock options new employees

Sentiment note

The article announces that Olema Pharmaceuticals has granted stock options to new employees, which is a positive sign for the company's growth and expansion.

Positive Jan 2, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its President and CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is focused on developing targeted therapies for breast cancer, with its lead product candidate, palazestrant, currently in a Phase 3 clinical trial.

OLMA Olema Pharmaceuticals breast cancer palazestrant clinical trial

Sentiment note

The article highlights Olema Pharmaceuticals' progress in developing targeted therapies for breast cancer, with its lead product candidate, palazestrant, in a Phase 3 clinical trial. This suggests the company is making advancements in its pipeline and is well-positioned to potentially transform the standard of care for breast cancer patients.

Positive Dec 10, 2024 • 12:00 UTC GlobeNewswire Inc. • Olema Oncology

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology presented updated clinical results for its drug palazestrant in combination with ribociclib, showing promising clinical activity and a favorable safety profile in patients with ER+/HER2- advanced or metastatic breast cancer.

OLMA Olema Oncology palazestrant ribociclib ER+/HER2- breast cancer

Sentiment note

The article presents positive clinical results for Olema Oncology's drug palazestrant in combination with ribociclib, indicating promising efficacy and a favorable safety profile in treating ER+/HER2- advanced or metastatic breast cancer.

Positive Sep 4, 2024 • 20:49 UTC GlobeNewswire Inc. • N/A

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted stock options to five new employees to purchase a total of 130,600 shares of the company's common stock.

OLMA Olema Pharmaceuticals stock options new employees

Sentiment note

The article announces that Olema Pharmaceuticals has granted stock options to new employees, which is a positive sign for the company's growth and expansion.

Positive Aug 21, 2024 • 11:00 UTC GlobeNewswire Inc. • N/A

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its management team will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024.

OLMA Olema Pharmaceuticals investor conference clinical-stage biopharmaceutical company

Sentiment note

The article announces Olema Pharmaceuticals' participation in an upcoming investor conference, which suggests the company is actively engaging with investors and is likely in a positive position to share updates on its business and pipeline.